1129540-72-2

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
1-(4-AMINO-PHENYL)-3-BROMO-1,2,4-TRIAZOLE is used as a building block for the production of various pharmaceuticals and agrochemicals due to its unique chemical structure and properties.
Used in Organic Synthesis:
1-(4-AMINO-PHENYL)-3-BROMO-1,2,4-TRIAZOLE is used as a precursor for the synthesis of diverse heterocycles and dyes, contributing to the development of new compounds with potential applications in various fields.
Used in Antifungal and Antimicrobial Applications:
1-(4-AMINO-PHENYL)-3-BROMO-1,2,4-TRIAZOLE has been studied for its potential antifungal and antimicrobial properties, making it a candidate for use in the development of new treatments against fungal and bacterial infections.
Safety and Handling:
As with any chemical compound, proper handling and storage of 1-(4-amino-phenyl)-3-bromo-1,2,4-triazole is necessary to prevent any potential hazards and ensure its safe use in research and industrial applications.

Upstream product

• 1129540-71-1 3-bromo-1-(4-nitrophenyl)-1H-1,2,4-triazole 

Downstream Products

• 1128096-85-4 N-(4-(3-bromo-1H-1,2,4-triazol-1-yl)phenyl)-4-(3-morpholinophenyl)pyrimidin-2-amine 
• 1128096-62-7 N-(4-(3-bromo-1H-1,2,4-triazol-1-yl)phenyl)-4-(3-fluoro-5-morpholinophenyl)pyrimidin-2-amine 

Relevant academic research and scientific papers

MOLECULES HAVING CERTAIN PESTICIDAL UTILITIES, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES RELATED THERETO

This disclosure relates to compounds having pesticidal utility against pests in phyla Nematoda, Arthropoda, and/or Mollusca, processes to produce such compounds and intermediates used in such processes, compositions containing such compounds, and processes of using such compounds against such pests. These compounds/molecules may be used, for example, as nematicides, acaricides, insecticides, miticides, and/or molluscicides. This document discloses compounds having the following formula (Formula One and/or Formula One-A).

Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors

Given the significant body of data supporting an essential role for c-jun-N-terminal kinase (JNK) in neurodegenerative disorders, we set out to develop highly selective JNK inhibitors with good cell potency and good brain penetration properties. The structure-activity relationships (SAR) around a series of aminopyrimidines were evaluated utilizing biochemical and cell-based assays to measure JNK inhibition and brain penetration in mice. Microsomal stability in three species, P450 inhibition, inhibition of generation of reactive oxygen species (ROS), and pharmacokinetics in rats were also measured. Compounds 9g, 9i, 9j, and 9l had greater than 135-fold selectivity over p38, and cell-based IC50 values 50 = 0.8 nM for inhibition of ROS and had good pharmacokinetic properties in rats along with a brain-to-plasma ratio of 0.75. These results suggest that biaryl substituted aminopyrimidines represented by compound 9l may serve as the first small molecule inhibitors to test efficacy of JNK inhibitors in neurodegenerative disorders. 2009 American Chemical Society.

SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS

The present invention provides novel substituted pyrimidinyl-amines that are useful as inhibitors of protein kinases, especially c-Jun N-terminal kinases (JNK) and pharmaceutical compositions thereof and methods of using the same for treating conditions responsive to the inhibition of the JNK pathway.